Nivolumab
Nivolumab keeps cancer cells from suppressing the immune system by binding to and blocking the protein PD-1 on the surface of some cancer cells. This allows the immune system to attack the cancer cells. Nivolumab is a type of immunotherapy drug called an immune checkpoint inhibitor.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Nivolumab is approved to treat:
- classic Hodgkin lymphoma. Nivolumab is used:
- alone in adults whose cancer has come back or has gotten worse and who underwent an autologous stem cell transplant and treatment with brentuximab vedotin
- alone in adults whose cancer has come back or has gotten worse and who received at least three other types of treatment including an autologous stem cell transplant
- with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine in adults and children aged 12 years and over who have not received treatment for stage III or stage IV cancer
- colorectal cancer in adults and children aged 12 years and older whose cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Nivolumab is used:
- alone in patients whose cancer has spread to other parts of the body and got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
- with ipilimumab in patients whose cancer has spread to other parts of the body or cannot be removed by surgery
- esophageal cancer. Nivolumab is used in adults:
- for certain esophageal cancers that have been treated with chemoradiation and then surgery to completely remove the cancer, but cancer cells were found in the removed tissue
- for squamous cell carcinoma of the esophagus that cannot be removed by surgery or has spread or come back after treatment with a fluoropyrimidine and platinum chemotherapy
- for squamous cell carcinoma of the esophagus that has the PD-L1 protein and cannot be removed by surgery or has spread to other parts of the body. It is given with either ipilimumab or a fluoropyrimidine and platinum chemotherapy as the first treatment.
- gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer that has the PD-L1 protein and has spread. Nivolumab is used with a fluoropyrimidine and platinum chemotherapy.
- hepatocellular carcinoma (a type of liver cancer) in adults whose cancer cannot be removed by surgery or has spread to other parts of the body. Nivolumab is used with ipilimumab as the first treatment or after treatment with sorafenib.
- malignant pleural mesothelioma. Nivolumab is used with ipilimumab as the first treatment in adults whose cancer cannot be removed by surgery.
- melanoma. Nivolumab is used:
- alone or with ipilimumab in adults and children aged 12 years and older whose cancer cannot be removed by surgery or has spread to other parts of the body
- to keep the cancer from coming back after surgery that completely removed the cancer in adults and children aged 12 years and older with one of the following stages of melanoma: stage IIB, IIC, IIIA, IIIB, IIIC, IIID, or IV
- non-small cell lung cancer in adults. Nivolumab is used:
- with platinum chemotherapy before surgery for early-stage cancer to keep the cancer from coming back
- with platinum chemotherapy before surgery for cancer that does not have an abnormal EGFR or ALK gene. It is also given alone after surgery to keep the cancer from coming back.
- as the first treatment with ipilimumab for cancer that has spread to other parts of the body and has the PD-L1 protein but does not have an abnormal EGFR or ALK gene
- as the first treatment with ipilimumab and platinum chemotherapy for cancer that has come back or spread to other parts of the body and does not have an abnormal EGFR or ALK gene
- for cancer that has spread to other parts of the body and has gotten worse during or after treatment with platinum chemotherapy. Patients whose cancer has an abnormal EGFR or ALK gene should receive nivolumab only if their cancer got worse after treatment with FDA-approved therapy for these gene mutations.
- renal cell carcinoma (a type of kidney cancer) that is advanced. Nivolumab is used in adults:
- who have already received angiogenesis inhibitor therapy
- with cabozantinib-s-malate as the first treatment
- with ipilimumab as the first treatment in some patients
- squamous cell carcinoma of the head and neck in adults whose cancer has either spread to other parts of the body or has come back or worsened during or after treatment with platinum chemotherapy
- urothelial carcinoma (a type of cancer in the bladder or urinary tract) in adults. Nivolumab is used:
- with cisplatin and gemcitabine as the first treatment for cancer that cannot be removed by surgery or has spread to other parts of the body
- after surgery to remove cancer that has a high risk of coming back
- for cancer that has spread and got worse after treatment with platinum chemotherapy
Nivolumab is given by infusion. It is available in a different form, combined with hyaluronidase, that is given subcutaneously. For more information, see the Drug Information Summary for Nivolumab and Hyaluronidase-nvhy. Nivolumab is also available as a combination formulation with a drug called relatlimab. For more information, see the Drug Information Summary for Nivolumab and Relatlimab-rmbw.
Nivolumab is also being studied in the treatment of other types of cancer.
More About Nivolumab
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Nivolumab - A lay language summary of important information about this drug.
Research Results and Related Resources
FDA Approval Likely to Change Initial Treatment for Some People with Advanced Colorectal Cancer
Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma
Trial Establishes Preferred Treatment for Some People with Esophageal Cancer
What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials
A Better Biomarker for Cancer Immunotherapy?
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Nivolumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.